Eli Lilly and Company (NYSE:LLY) Shares Sold by Tilt Investment Management Holdings PBC

Tilt Investment Management Holdings PBC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 20.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,271 shares of the company’s stock after selling 861 shares during the quarter. Eli Lilly and Company makes up approximately 2.1% of Tilt Investment Management Holdings PBC’s investment portfolio, making the stock its 8th largest position. Tilt Investment Management Holdings PBC’s holdings in Eli Lilly and Company were worth $1,907,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Lipe & Dalton bought a new stake in Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the 3rd quarter valued at $27,000. Retirement Group LLC raised its stake in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares during the period. Cornerstone Planning Group LLC bought a new position in Eli Lilly and Company during the 2nd quarter worth $33,000. Finally, Legacy Financial Group LLC bought a new position in Eli Lilly and Company during the 3rd quarter worth $35,000. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.13% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. Finally, JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Trading Down 0.8 %

LLY stock traded down $6.32 during midday trading on Thursday, reaching $744.45. 990,506 shares of the company traded hands, compared to its average volume of 3,057,192. Eli Lilly and Company has a 52-week low of $367.35 and a 52-week high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business has a 50 day moving average of $764.03 and a 200-day moving average of $657.67. The firm has a market capitalization of $707.35 billion, a price-to-earnings ratio of 129.32, a P/E/G ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the business posted $2.09 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, sell-side analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.